R&D at other companies
Other financials
Where this comes from
Reported directly by Artiva Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Artiva Biotherapeutics, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Artiva Biotherapeutics, Inc.'s R&D?
- Artiva Biotherapeutics, Inc. (ARTV) reported R&D of $19.31M in Q1 2026.
- How has Artiva Biotherapeutics, Inc.'s R&D changed year-over-year?
- Artiva Biotherapeutics, Inc.'s R&D increased by 13.3% year-over-year, from $17.05M to $19.31M.
- What is the long-term trend for Artiva Biotherapeutics, Inc.'s R&D?
- Over 2 years (2023 to 2025), Artiva Biotherapeutics, Inc.'s R&D has grown at a 17.6% compound annual growth rate (CAGR), from $50.25M to $69.54M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.